PriceTargets.com logo

Aclarion - ACON Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $1.30
  • Forecasted Upside: 1,055.56%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.11 As of 12/17/2024 01:00 AM ET
▲ +0.01 (9.76%)

This chart shows the closing price for ACON by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aclarion Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ACON and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ACON

Analyst Price Target is $1.30
▲ +1,055.56% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Aclarion in the last 3 months. The average price target is $1.30, with a high forecast of $1.30 and a low forecast of $1.30. The average price target represents a 1,055.56% upside from the last price of $0.11.

This chart shows the closing price for ACON for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 2 polled investment analysts is to moderate buy stock in Aclarion. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/20/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/18/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/17/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/17/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/13/2024Maxim GroupReiterated RatingBuy ➝ Hold
11/27/2024Ascendiant Capital MarketsLower TargetBuy ➝ Buy$1.50 ➝ $1.30
8/26/2024Ascendiant Capital MarketsReiterated RatingBuy ➝ Buy$1.60 ➝ $1.50
7/29/2024Ascendiant Capital MarketsInitiated CoverageBuy$1.60
7/6/2022Maxim GroupInitiated CoverageBuy$48.00
(Data available from 12/17/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/20/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/20/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/19/2024
  • 0 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/18/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/18/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/17/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/17/2024

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Aclarion logo
Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
Read More

Today's Range

Now: $0.11
Low: $0.10
High: $0.11

50 Day Range

MA: $0.17
Low: $0.10
High: $0.23

52 Week Range

Now: $0.11
Low: $0.10
High: $7.40

Volume

848,037 shs

Average Volume

1,412,837 shs

Market Capitalization

$1.17 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.44

Frequently Asked Questions

What sell-side analysts currently cover shares of Aclarion?

The following Wall Street research analysts have issued research reports on Aclarion in the last twelve months: Ascendiant Capital Markets, and Maxim Group.
View the latest analyst ratings for ACON.

What is the current price target for Aclarion?

0 Wall Street analysts have set twelve-month price targets for Aclarion in the last year. Their average twelve-month price target is $1.30, suggesting a possible upside of 1,055.6%. Ascendiant Capital Markets has the highest price target set, predicting ACON will reach $1.30 in the next twelve months. Ascendiant Capital Markets has the lowest price target set, forecasting a price of $1.30 for Aclarion in the next year.
View the latest price targets for ACON.

What is the current consensus analyst rating for Aclarion?

Aclarion currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ACON.

What other companies compete with Aclarion?

Other companies that are similar to Aclarion include ATI Physical Therapy, CareMax, IMAC, NewGenIvf Group and Greenbrook TMS. Learn More about companies similar to Aclarion.

How do I contact Aclarion's investor relations team?

Aclarion's physical mailing address is 951 MARINERS ISLAND BLVD STE 300, SAN MATEO CA, 94404. The company's listed phone number is 833-275-2266. The official website for Aclarion is www.aclarion.com. Learn More about contacing Aclarion investor relations.